Table 1 Characteristics of the studies
Year | 2004 (n = 13) | 2009 (n = 28) | 2014 (n = 39) | p | All studies (n = 80) |
|---|---|---|---|---|---|
5-year Impact factora | 2.967 (2.447/4.625) | 4.206 (2.455/4.626) | 2.179 (1.647/3.503) | .011b | 2.784 (2.130/4.626) |
Trial registeredc | 0 (0.0) | 2 (7.1) | 12 (30.8) | .009d | 14 (17.5) |
Sample sizea | 28 (20.0/47.0) | 39 (31.5/65.0) | 34 (23.0/52.5) | .212b | 38 (23.5/56.5) |
Intervention groupsc | |||||
2 groups | 11 (84.6) | 21 (75.0) | 34 (87.2) | .418d | 66 (82.5) |
≥ 3 groups | 2 (15.4) | 7 (25.0) | 5 (12.8) | 14 (17.5) | |
Etiologyc | |||||
Ischemic | 1 (7.7) | 8 (28.6) | 5 (12.8) | 14 (17.5) | |
Hemorrhagic | 0 (0.0) | 0 (0.0) | 1 (2.6) | .305d | 1 (1.2) |
Mixed | 7 (53.8) | 16 (57.1) | 21 (53.8) | 44 (55.0) | |
None declared | 5 (38.5) | 4 (14.3) | 12 (30.8) | 21 (26.2) | |
Phase of the disease-onsetc | |||||
< 6 months | 4 (30,8) | 15 (53.6) | 14 (35.9) | 33 (41.2) | |
≥ 6 months | 8 (61.5) | 12 (42.9) | 23 (59.0) | .516d | 43 (53.8) |
None declared | 1 (7.7) | 1 (3.6) | 2 (5.1) | 4 (5.0) | |
Placebo-sham comparatorc | 2 (15.4) | 5 (17.9) | 9 (23.1) | .807d | 16 (20.0) |
Intervention dosing-hoursae | 18.0 (6.0/22.5) | 15.5 (11.0/27.0) | 24.0 (10.0/34.7) | .139b | 18.0 (9.0/30.0) |
At least one outcomec | |||||
Favorable | 9 (69.2) | 20 (71.4) | 25 (64.1) | .855d | 54 (67.5) |
Nonsignificant | 11 (84.6) | 25 (89.3) | 36 (92.3) | .614d | 72 (90.0) |
Unfavorable | 1 (7.7) | 1 (3.6) | 3 (7.7) | .705d | 5 (6.2) |
PEDro scorea | 6 (5.0/6.0) | 6 (5.0/7.0) | 6 (5.0/7.5) | .073b | 6 (5.0/7.0) |